{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:50:04Z","timestamp":1783641004951,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00777-z","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:30:18Z","timestamp":1749598218000},"page":"1553-1567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02610868","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6466","authenticated-orcid":false,"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Molho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Dashtipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon A.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredy J.","family":"Revilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peibing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the OPen Label Trial of Intraglandular MYobloc injections for Sialorrhea Treatment (OPTIMYST) study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinky","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Criswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgilio Gerald","family":"Evidente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Grill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Klepitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Klos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Dale","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"LeDoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo D.","family":"Moguel-Cobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Savitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaryna","family":"Brozhyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Buchakchyiska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmyla","family":"Dzyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriia","family":"Gryb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Khubetova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanosh","family":"Sanotskyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volodymyr","family":"Smolanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Voloshyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Alekseenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Dubenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigmund","family":"Gedrevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Likhachev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siarhei","family":"Lialikau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsyana","family":"Mikhailava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Mitkovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volha","family":"Moguchaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Shelepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"issue":"9","key":"777_CR1","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00415-009-5098-2","volume":"256","author":"JG Kalf","year":"2009","unstructured":"Kalf JG, de Swart BJ, Borm GF, Bloem BR, Munneke M. Prevalence and definition of drooling in Parkinson\u2019s disease: a systematic review. J Neurol. 2009;256(9):1391\u20136.","journal-title":"J Neurol"},{"issue":"11","key":"777_CR2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson\u2019s disease symptoms: the patient\u2019s perspective. Mov Disord. 2010;25(11):1646\u201351.","journal-title":"Mov Disord"},{"issue":"2","key":"777_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/mus.21213","volume":"39","author":"CE Jackson","year":"2009","unstructured":"Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39(2):137\u201343.","journal-title":"Muscle Nerve"},{"issue":"6","key":"777_CR4","first-page":"400","volume":"62","author":"JB Epstein","year":"2012","unstructured":"Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012;62(6):400\u201322.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"777_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40263-019-00612-8","volume":"33","author":"SY Chen","year":"2019","unstructured":"Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33(3):225\u201338.","journal-title":"CNS Drugs"},{"issue":"16","key":"777_CR6","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/mds.21752","volume":"22","author":"AG Postma","year":"2007","unstructured":"Postma AG, Heesters M, van Laar T. Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Mov Disord. 2007;22(16):2430\u20135.","journal-title":"Mov Disord"},{"issue":"7","key":"777_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.parkreldis.2009.12.003","volume":"16","author":"J Leibner","year":"2010","unstructured":"Leibner J, Ramjit A, Sedig L, et al. The impact of and the factors associated with drooling in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2010;16(7):475\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"777_CR8","first-page":"2628","volume":"69","author":"NG Hockstein","year":"2004","unstructured":"Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Phys. 2004;69(11):2628\u201334.","journal-title":"Am Fam Phys"},{"issue":"19","key":"777_CR9","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","volume":"70","author":"M Naumann","year":"2008","unstructured":"Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707\u201314.","journal-title":"Neurology"},{"issue":"2","key":"777_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/0194599812465059","volume":"148","author":"R Vashishta","year":"2013","unstructured":"Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. Otolaryngol Head Neck Surg. 2013;148(2):191\u20136.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"17","key":"777_CR11","doi-asserted-by":"publisher","first-page":"e1982","DOI":"10.1212\/WNL.0000000000007368","volume":"92","author":"WH Jost","year":"2019","unstructured":"Jost WH, Friedman A, Michel O, et al. SIAXI: placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019;92(17):e1982\u201391.","journal-title":"Neurology"},{"key":"777_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40734-017-0055-1","volume":"4","author":"K Dashtipour","year":"2017","unstructured":"Dashtipour K, Bhidayasiri R, Chen JJ, Jabbari B, Lew M, Torres-Russotto D. RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. J Clin Mov Disord. 2017;4:9.","journal-title":"J Clin Mov Disord"},{"issue":"4","key":"777_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","volume":"77","author":"SH Isaacson","year":"2020","unstructured":"Isaacson SH, Ondo W, Jackson CE, et al. Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial. JAMA Neurol. 2020;77(4):461\u20139.","journal-title":"JAMA Neurol"},{"issue":"2","key":"777_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.23929","volume":"27","author":"R Chinnapongse","year":"2012","unstructured":"Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson\u2019s disease: a prospective double-blind trial. Mov Disord. 2012;27(2):219\u201326.","journal-title":"Mov Disord"},{"key":"777_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.parkreldis.2019.11.024","volume":"70","author":"WH Jost","year":"2020","unstructured":"Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, et al. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks. Parkinsonism Relat Disord. 2020;70:23\u201330.","journal-title":"Parkinsonism Relat Disord"},{"key":"777_CR16","unstructured":"US Food and Drug Administration. XEOMIN (incobotulinumtoxinA) for injection, for intramuscular or intraglandular use. Precribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125360s073lbl.pdf. Accessed 15 Aug 2024."},{"key":"777_CR17","unstructured":"US Food and Drug Administration. MYOBLOC\u00ae (rimabotulinumtoxinB) injection, for intramuscular or intraglandular use. Prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103846s5190lbl.pdf. Accessed 15 Aug 2024."},{"issue":"1\u20132","key":"777_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2005.04.017","volume":"235","author":"R Bhidayasiri","year":"2005","unstructured":"Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci. 2005;235(1\u20132):1\u20139.","journal-title":"J Neurol Sci"},{"issue":"5","key":"777_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.toxicon.2009.03.009","volume":"54","author":"JC Arezzo","year":"2009","unstructured":"Arezzo JC. NeuroBloc\u00ae\/Myobloc\u00ae: unique features and findings. Toxicon. 2009;54(5):690\u20136.","journal-title":"Toxicon"},{"issue":"2","key":"777_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mds.20189","volume":"20","author":"M Proulx","year":"2005","unstructured":"Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson\u2019s disease. Mov Disord. 2005;20(2):204\u20137.","journal-title":"Mov Disord"},{"issue":"5","key":"777_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/mds.22260","volume":"24","author":"ML Evatt","year":"2009","unstructured":"Evatt ML, Chaudhuri KR, Chou KL, et al. Dysautonomia rating scales in Parkinson\u2019s disease: sialorrhea, dysphagia, and constipation\u2014critique and recommendations by movement disorders task force on rating scales for Parkinson\u2019s disease. Mov Disord. 2009;24(5):635\u201346.","journal-title":"Mov Disord"},{"issue":"2","key":"777_CR22","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1111\/j.1469-8749.2009.03519.x","volume":"52","author":"SM Reid","year":"2010","unstructured":"Reid SM, Johnson HM, Reddihough DS. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol. 2010;52(2):e23\u20138.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"777_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1212\/01.WNL.0000101713.81253.4C","volume":"62","author":"WG Ondo","year":"2004","unstructured":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease. Neurology. 2004;62(1):37\u201340.","journal-title":"Neurology"},{"issue":"3","key":"777_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/scd.12671","volume":"42","author":"K Lansdown","year":"2022","unstructured":"Lansdown K, Irving M, Mathieu Coulton K, Smithers-Sheedy H. A scoping review of oral health outcomes for people with cerebral palsy. Spec Care Dentist. 2022;42(3):232\u201343.","journal-title":"Spec Care Dentist"},{"issue":"12","key":"777_CR25","volume":"15","author":"N AlMadan","year":"2023","unstructured":"AlMadan N, AlMajed A, AlAbbad M, AlNashmi F, Aleissa A. Dental management of patients with amyotrophic lateral sclerosis. Cureus. 2023;15(12):e50602.","journal-title":"Cureus"},{"issue":"4","key":"777_CR26","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3233\/JPD-212605","volume":"11","author":"M Auffret","year":"2021","unstructured":"Auffret M, Meuric V, Boyer E, Bonnaure-Mallet M, Verin M. Oral health disorders in Parkinson\u2019s disease: more than meets the eye. J Parkinsons Dis. 2021;11(4):1507\u201335.","journal-title":"J Parkinsons Dis"},{"issue":"7","key":"777_CR27","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3233\/JPD-230059","volume":"13","author":"Y Chen","year":"2023","unstructured":"Chen Y, Jin Y, Li K, Qiu H, Jiang Z, Zhu J, et al. Is there an association between Parkinson\u2019s disease and periodontitis? A systematic review and meta-analysis. J Parkinsons Dis. 2023;13(7):1107\u201325.","journal-title":"J Parkinsons Dis"},{"key":"777_CR28","first-page":"19","volume":"9","author":"G Garuti","year":"2019","unstructured":"Garuti G, Rao F, Ribuffo V, Sansone VA. Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis. 2019;9:19\u201326.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"9","key":"777_CR29","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/mds.10484","volume":"18","author":"BA Racette","year":"2003","unstructured":"Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord. 2003;18(9):1059\u201361.","journal-title":"Mov Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00777-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:09:13Z","timestamp":1757185753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00777-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00777-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rajesh Pahwa is a member of the Editorial Board of Neurology and Therapy. Rajesh Pahwa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Rajesh Pahwa, Eric Molho, Khashayar Dashtipour, Ramon A Gil, Fredy J Revilla, and Stuart H Isaacson were all investigators in the OPTIMYST study and report fees for consultancy from Supernus Pharmaceuticals, Inc. Rajesh Pahwa reports grants from Abbott, AbbVie, Alexza, Annovis, Biogen, Bluerock, Bukwang, Cerevel, Global Kinetics, Jazz, the Michael J Fox Foundation, NeuroDerm, Neuraly, the Parkinson\u2019s Foundation, Praxis, Roche, Sage, Scion, Sun Pharma, UCB, and Voyager; and consulting fees from Abbott, AbbVie, ACADIA, Acorda, Allevion, Amneal, Artemida, BioVie, CalaHealth, Convatec, Global Kinetics, Inbeeo, Insightec, Jazz, Kyowa, Lundbeck, Merz, Neurocrine, NeuroDerm, Ono, PhotoPharmics, Sage, Sunovion, Supernus, UCB, and Wren. Eric Molho reports consultancy fees from CNS Ratings; speaker fees from Neurocrine Biosciences; research grants from Impax Pharmaceuticals, Civitas Therapeutics, Cure Huntington\u2019s Disease Initiative, Michael J Fox Foundation, Biogen, Acorda Therapeutics, Biohaven Pharmaceuticals; and an educational grant from Merz Neurosciences. Mark Lew reports consultancy for Supernus Pharmaceuticals, Inc., Neurocrine, Acorda, Kyowa, Amneal, UCB, Merz, Acadia, and Abbvie; and research grants from the Michael J Fox Foundation, Neuraly, NIAA, Jazz Pharmaceuticals, UCB, Inhibikase Therapeutics, Biogen, and Ono Pharma. Khashayar Dashtipour has received compensation to serve as an advisor and\/or speaker from Allergan, Acadia, Abbvie, Acorda, Amneal, Cynapsus, Ipsen, Kyowa Kirin, Lundbeck, Neurocrine, Revance, Supernus, Teva, and US WorldMeds. Ramon A Gil reports fees for speaking engagements consultancy from US WorldMeds, LLC. Fredy J Revilla reports consultancy fees from US WorldMeds, LLC. Stuart Isaacson reports receipt of grants and\/or research support from Abbvie, Amneal, Bial, Biogen, Ipsen, Lundbeck, Michael J Fox Foundation, Neurocrine, Neuroderm, Parkinson Study Group, Revance, Roche, Supernus, Teva, Theravance, and UCB; receipt of consulting fees from Abbvie, Acadia, Amneal, Cerevance, Kirin, Merz, Neurocrine, Neuroderm, Revance, Roche, Supernus, Teva, and UCB; and participation in a company sponsored speaker\u2019s bureau for Abbvie, Acadia, Amneal, Kyowa Kirin, Merz, Neurocrine, Supernus, and Teva. Thomas Clinch was an employee of US WorldMeds, LLC (currently MDD, US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc.) at the time the study was conducted. His current affiliation is USWM, LLC (Louisville, KY, USA). Peibing Qin is an employee of Supernus Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review boards at the participating sites approved the protocol, and the trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}